Imigran

Sumatriptan succinate, the active ingredient in Imigran, is a Triptan (selective 5‑HT1B/1D receptor agonist) presented as a 6 mg/0.5 mL autoinjector for subcutaneous use. It provides acute treatment of migraine attacks, with or without aura, in adult patients.

GNH USA supplies Imigran as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, meeting EU market standards for quality and safety. The company ensures consistent batch release and regulatory compliance across all shipments.

Imigran (sumatriptan succinate) is indicated for the acute management of migraine, a common neurovascular headache disorder that involves serotonin‑mediated vasodilation and neurogenic inflammation.

Migraine with aura: provides rapid relief of headache and associated visual or sensory disturbances. Migraine without aura: reduces pain intensity and duration when taken early in an attack. Acute migraine attacks: aborts an ongoing episode and improves functional ability. Cluster headache (off‑label): sometimes used in clinical practice, though not a primary indication.

Common Side Effects: - Injection site pain or erythema - Tingling or numbness in the face or extremities - Warmth or flushing sensation - Nausea or mild stomach upset - Dizziness or light‑headedness - Fatigue or general weakness

Serious or Rare Side Effects: - Chest pain or tightness suggesting coronary vasospasm - Severe hypertension or hypertensive crisis - Serotonin syndrome, especially with other serotonergic agents - Allergic reactions, including rash, swelling, or anaphylaxis - Cardiac arrhythmias or myocardial infarction in susceptible individuals - Severe or persistent abdominal pain

Imigran should be used with caution in patients who have cardiovascular risk factors or established disease. - Cardiovascular disease: avoid use in uncontrolled hypertension, ischemic heart disease, or recent myocardial infarction. - History of stroke or transient ischemic attack: contraindicated due to risk of cerebral vasoconstriction. - Concomitant serotonergic drugs: monitor for signs of serotonin syndrome. - Pregnancy: safety not established; prescribe only if potential benefit outweighs risk. - Pediatric use: not established; avoid in children and adolescents. Store at ambient temperature: keep in original packaging, protect from moisture and light.

Imigran may interact with several drug classes that affect serotonin pathways or vascular tone.

Major Interactions (Avoid): - Ergot derivatives: additive vasoconstriction may precipitate ischemia. - Monoamine oxidase inhibitors (MAOIs): increased risk of serotonin syndrome. - Selective serotonin reuptake inhibitors (SSRIs) and serotonin‑norepinephrine reuptake inhibitors (SNRIs): heightened serotonin toxicity.

Moderate Interactions (Monitor Closely): - Combination of multiple triptans: cumulative vasoconstrictive effect. - Other serotonergic agents (e.g., trazodone, linezolid): monitor for serotonin syndrome symptoms.